Blog
Before Anything Can Be Prescribed
Diagnosis is the first of the 10 Exits of Therapy™, and it is the only one where nothing has gone wrong yet, because nothing has started. Everything that follows in your care runs off a diagnosis written in your record. Until something has a name, there is no...
The Launch Begins Long Before Approval Day
Payers form a view of a therapy years before a commercial team is allowed to make its case. Since 2023 federal law has made pre-approval exchange explicit, within defined limits, and most organizations still do not use the window.
A Launch Does Not Fail in the Forecast. It Fails in the Exits.
Half of a launch class misses its first-year forecast. The miss is rarely in the model. It is in the commercial infrastructure a new product does not have yet, and in the bridge supply that hides the shortfall until the decisions are already locked.
Rethinking Copay Accumulators: Focus on Days-on-Therapy Over Dollars Spent
The true cost of copay accumulators extends beyond immediate financial metrics.
The Many Faces of 340B
Transparency, tension and the future of pharmaceutical access. Four stakeholders describe 340B four different ways, and every one of them is accurate. The gap between those descriptions is where the conflict lives.
Government Pricing Is No Longer a Calculation. It Is a Transaction.
Medicare’s Maximum Fair Price and the revised 340B rebate pilot move the federal discount behind the dispense. From January 1, 2027, the claim is what substantiates it, and the patient journey is what creates the claim.
The Frameworks Behind the Profile
CEOInsider published a profile of this work without naming a single framework in it. That was the right editorial call. Here is the key.
Aligning Patient Support Services with Gross-to-Net Strategy
Gross-to-Net is discussed as an accounting output. It is the financial manifestation of dozens of decisions made long before the first prescription is written.
The Pharmacy of the Future Will Not Compete on Dispensing. It Will Compete on Value.
The short version: a pharmacy built on dispensing volume is easy to exploit and hard to defend, and enforcement actions and CMS quality measures already reward outcomes over counts. The pharmacy of the future will be paid for moving patients successfully through...
Close Cycle Automation
Automating a close you have not simplified buys you the same close, faster, and makes it permanent.